Trial Profile
Phase II Randomized Controlled Trial of Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 01 Nov 2017 Status changed from active, no longer recruiting to discontinued.
- 19 May 2016 Status changed from recruiting to active, no longer recruiting.
- 19 May 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017.